IXAKA LIMITED

Adaptimmune Undergoes Major Leadership Restructuring Following Nasdaq Delisting and Asset Divestiture

- Christopher Hill has been appointed as both CEO and CFO of Adaptimmune, succeeding Adrian Rawcliffe who departed as part of the company's restructuring efforts. - The company's board has been significantly reduced to three members following the resignation of six directors, with Lawrence Alleva taking over as Chairman from David Mott. - Adaptimmune voluntarily delisted from Nasdaq in October 2025 and is now trading on the OTC Pink market, with deregistration expected to become effective around January 26, 2026. - The restructuring follows the July 2025 divestiture of TECELRA and other key cell therapy assets to US WorldMeds, leaving Adaptimmune to focus on maximizing value from remaining PRAME and CD70-targeted programs.